Apotex Says To High Court: Amgen Gets To Reap Profits From Unfair Statutory Period
WASHINGTON, D.C. — Apotex Inc. and Apotex Corp. (collectively, Apotex) argue in a Nov. 21 reply brief to the U.S. Supreme Court that biotechnology companies that lost an underlying patent case...To view the full article, register now.
Already a subscriber? Click here to view full article